Sensus Healthcare Inc (NASDAQ:SRTS) – Analysts at B. Riley boosted their FY2020 earnings per share (EPS) estimates for Sensus Healthcare in a note issued to investors on Friday, August 9th. B. Riley analyst A. D’silva now expects that the company will post earnings per share of $0.42 for the year, up from their prior forecast of $0.33.
Sensus Healthcare (NASDAQ:SRTS) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.06. Sensus Healthcare had a negative return on equity of 8.89% and a negative net margin of 8.65%. The business had revenue of $7.48 million during the quarter, compared to analysts’ expectations of $8.04 million.
Sensus Healthcare stock opened at $6.01 on Monday. The firm has a 50-day simple moving average of $5.35. Sensus Healthcare has a 12-month low of $4.75 and a 12-month high of $9.23. The company has a market capitalization of $98.09 million, a PE ratio of -42.93 and a beta of -0.21.
Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. lifted its position in Sensus Healthcare by 40.7% in the second quarter. BlackRock Inc. now owns 103,643 shares of the company’s stock worth $574,000 after purchasing an additional 29,990 shares during the period. Heartland Advisors Inc. lifted its position in Sensus Healthcare by 150.0% in the second quarter. Heartland Advisors Inc. now owns 375,000 shares of the company’s stock worth $2,078,000 after purchasing an additional 225,000 shares during the period. Wells Fargo & Company MN bought a new position in Sensus Healthcare in the second quarter worth $30,000. B. Riley Wealth Management Inc. bought a new position in Sensus Healthcare in the first quarter worth $117,000. Finally, B. Riley Financial Inc. bought a new position in Sensus Healthcare in the first quarter worth $281,000. Hedge funds and other institutional investors own 9.53% of the company’s stock.
About Sensus Healthcare
Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
See Also: Percentage Gainers
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.